Jump to content

New Ipilimumab Trial in Australia

Paul Edwards

Recommended Posts

Ipilimumab (brand name Yervoy) is an immunotherapy approach to the treatment of cancer.


Ipilimumab was the first treatment ever proven to extend survival in patients with metastatic melanoma, the deadliest form of skin cancer, and has been approved by the Australian Pharmaceutical Benefits Scheme for that treatment.


Ipilimumab was tested in two phase III trials as a treatment for advanced, castration-resistant prostate cancer.  


In the patients receiving Ipilimumab after docetaxel, the drug failed to improve overall survival.  Results of the trial in which patients received Ipilimumab prior to chemotherapy are not yet available.  Ipilimumab is also now being tested in several phase II trials.


One of these trials is a “Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive”.


Details of this trial are available at the ClinicalTrials.gov site Identifier: NCT02279862.



The trial is being conducted at 6 Australian locations in Melbourne, Sydney and Perth.  One of the Melbourne locations has commenced recruitment.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...